Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

It’s Not Just Joint Pain

Mary Beth Nierengarten  |  November 19, 2024

Experts offered perspectives on how symptoms of rheumatic disease, such as fatigue, affect the physical, cognitive and emotional health of patients and offered solutions.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024Exercisefatiguehealthy eatingpatient carequality of life

The Management of Psoriatic Arthritis: A Review

Samantha C. Shapiro, MD  |  November 17, 2024

WASHINGTON, D.C.—As of November 2024, there are 16 biologic disease-modifying anti-rheumatic drugs (bDMARDs) that are FDA approved for the treatment of psoriatic arthritis (PsA). Incredible news, right? But as my fellowship program director used to say, “There’s no free lunch.” This buffet of options is excellent for our patients, but poses challenges to the practicing…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 PsA

AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM

By Matthew A. Sherman, MD, MHSc, & Stacey E. Tarvin, MD, MS  |  November 10, 2024

Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGuidelinesMyositisResearch ReviewsResearch Rheum Tagged with:juvenile dermatomyositisReading Rheum

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:EULAREULAR 2024Safetyupadacitinib

Type I IFNs in Cutaneous Lupus & Dermatomyositis

Katie Robinson  |  October 14, 2024

Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.

Filed under:ConditionsMyositis Tagged with:Immunologytype I interferon

Is Intestinal Dysbiosis Associated with RA?

ACR Open Rheumatology  |  October 9, 2024

This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.

Filed under:ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:dysbiosisRA Resource CenterTNF inhibitor

Interventions to Delay RA Onset

Ruth Jessen Hickman, MD  |  October 9, 2024

Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.

Filed under:ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:preventionRA Resource Center

Making Sense of Autoimmune Sensorineural Hearing Loss

Bryn Nelson, PhD  |  October 8, 2024

An unusual autoimmune inner ear condition results in hearing loss, but is reversible if treated.

Filed under:ConditionsOther Rheumatic ConditionsVasculitis Tagged with:autoimmune inner ear diseaseautoimmune sensorineural hearing loss (SNHL)hearing loss

Case Report: Amyloid Beta-Related Angiitis of the Central Nervous System

Alexandros Grivas, MD, Nikil Revuri, MD, Aleksandra Karaseva, MD, Basimah AlBalooshy, MD, & Andres M. Ponce, MD  |  October 8, 2024

Here, we present a case of inflammatory cerebral amyloid angiopathy, discussing its diverse clinical manifestations, diagnostic challenges in view of recently proposed clinical-radiologic criteria and its management.

Filed under:ConditionsOther Rheumatic ConditionsVasculitis Tagged with:amyloid β-related angiitiscase reportcentral nervous system vasculitiscerebral amyloid angiopathy

Your Gout Guide for ACR Convergence 2024: Dr. Lisa Stamp

Glen Rodman  |  September 25, 2024

Lisa Stamp, MBChB, PhD, is here to help the busy clinician by curating a collection of the most significant and notable abstracts in gout research to be presented at ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisGuidanceMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 goutGout

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences